Please assess the completion status of the following clinical trial:

Trial Title: 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants of 6 weeks of age (+7 days) on date of first vaccination~2. Healthy assessed from medical history and physical examination~3. One parent/guardian has been properly informed about the trial and has signed the informed consent form~4. One parent/guardian grants access to the infant's trial related medical records~5. One parent/guardian is likely to comply with trial procedures~Exclusion Criteria:~1. Vaccinated with poliovirus vaccine (OPV or IPV), other than the trial vaccines, prior to inclusion or planned during the trial (e.g. on national polio immunisation days)~2. OPV vaccination or known exposure to poliovirus in household (living together) within 3 month prior to inclusion or planned during the trial~3. Has a sibling who is ≤5 years of age, and for whom OPV vaccination is planned during the trial~4. Low birth weight (\< 2,500 g)~5. Known or suspected immunodeficiency (e.g. HIV, leukaemia, lymphoma) or family history of congenital or hereditary immunodeficiency~6. Severe uncontrolled chronic disease (e.g. neurologic, pulmonary, gastrointestinal, hepatic, renal or endocrine)~7. Known or suspected allergy to vaccine constituents (e.g. hypersensitivity to formaldehyde)~8. Acute severe febrile illness at day of vaccination deemed by the investigator to be a contraindication for vaccination~9. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections or blood sampling~10. Treatment with a product which is likely to modify the immune response (e.g. blood products and immunoglobulins) prior to inclusion or planned during the trial~11. Participating in another clinical trial~12. Not suitable for inclusion in the opinion of the investigator

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 49 Days
- Healthy Volunteers: t

Study Arms:
- 1/3 IPV-Al SSI (Type: EXPERIMENTAL): 3 vaccinations of 1/3 IPV-Al SSI given at 6, 10 and 14 weeks of age
- 1/5 IPV-Al SSI (Type: EXPERIMENTAL): 3 vaccinations of 1/5 IPV-Al SSI given at 6, 10 and 14 weeks of age
- 1/10 IPV-Al SSI (Type: EXPERIMENTAL): 3 vaccinations of 1/10 IPV-Al SSI given at 6, 10 and 14 weeks of age
- IPV Vaccine SSI (Type: ACTIVE_COMPARATOR): 3 vaccinations of IPV Vaccine SSI given at 6, 10 and 14 weeks of age, The comparator IPV Vaccine SSI contains: Type 1: 40DU, Type 2: 8 DU and Type 3: 32 DU.

Based on this trial design, predict the completion outcome and termination type (if applicable).